ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Filomicelle-Embedded Composite Hydrogels for Localized Gelation Within the Anterior Chamber of the Eye.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Recent Achievements and Perspectives in Nebulization Devices for Anterior Segment Disease Treatment.Pharmaceutics · 2026Review
- Filomicelle-Embedded Composite Hydrogels for Localized Gelation Within the Anterior Chamber of the Eye.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Hydrogels as Promising Carriers for Ophthalmic Disease Treatment: A Comprehensive Review.Gels (Basel, Switzerland) · 2026Review
Corrections and comments
- Update of
Authors and funding
7 authors.
Funding
Abstract
Anterior segment diseases, including glaucoma and uveitis, affect millions of patients worldwide. Nanocarriers hold transformative potential for treating these conditions, yet corneal epithelium impermeability necessitates intraocular injection. Given the discomfort and infection risk, an injectable hydrogel-based depot offers a promising strategy for sustained delivery. However, because the aqueous humor is a large, fluid-filled environment, achieving spatially confined gelation remains a key challenge, as injected materials rapidly diffuse. Herein, a composite hydrogel (C-gel) is presented that enables localized in situ gelation and sustained nanocarrier release within the anterior chamber. This is achieved by embedding poly(ethylene glycol)-b-poly(propylene sulfide) (PEG-b-PPS) filomicelles (FMs) within a crosslinked multi-arm PEG hydrogel. The FM structure facilitated the spatial confinement of DBCO- and azide-PEG crosslinking reactions, promoting efficient gel formation-the first use of FM morphology for enhanced localized gelation. As a result, 90% of the injected polymer is retained within the crosslinked matrix. Embedded FMs undergo oxidation-induced cylinder-to-sphere transitions, facilitating gradual release of micellar nanocarriers. The mechanical properties and release kinetics of C-gels can be specified by adjusting the formulation parameters. Sustained release of dye-loaded nanocarriers, used as a fluorescent model cargo, persisted for over a month under anterior chamber-mimicking conditions, underscoring the C-gel's potential as a long-acting depot for ocular drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.